Pharmacological options for the treatment of chronic migraine pain

被引：3
作者：
Urits, Ivan [1 ]
Gress, Kyle [2 ]
Charipova, Karina [2 ]
Zamarripa, Alec M. [3 ]
Patel, Parth M. [3 ]
Lassiter, Grace [2 ]
Jung, Jai Won [2 ]
Kaye, Alan D. [4 ]
Viswanath, Omar [3 ,4 ,5 ,6 ]
机构：
[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA
[2] Georgetown Univ, Sch Med, Washington, DC USA
[3] Univ Arizona, Dept Anesthesiol, Coll Med Phoenix, Phoenix, AZ USA
[4] Louisiana State Univ Hlth Shreveport, Dept Anesthesiol, Shreveport, LA USA
[5] Creighton Univ, Sch Med, Dept Anesthesiol, Omaha, NE USA
[6] Valley Pain Consultants Envision Phys Serv, Phoenix, AZ USA
来源：
BEST PRACTICE & RESEARCH-CLINICAL ANAESTHESIOLOGY | 2020年 / 34卷 / 03期
关键词：
migraine; preventive therapy; chronic pain; pharmacology; therapeutics; TOXIN TYPE-A; QUALITY STANDARDS SUBCOMMITTEE; LONG-TERM SAFETY; DOUBLE-BLIND; PREVENTIVE TREATMENT; PROPHYLACTIC TREATMENT; ANTINOCICEPTIVE ACTION; CENTRAL SENSITIZATION; ANTIEPILEPTIC DRUGS; ENERGY-METABOLISM;
D O I：
10.1016/j.bpa.2020.08.002
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
Migraine is a debilitating neurological condition with symptoms typically consisting of unilateral and pulsating headache, sensitivity to sensory stimuli, nausea, and vomiting. The World Health Organization (WHO) reports that migraine is the third most prevalent medical disorder and second most disabling neurological condition in the world. There are several options for preventive migraine treatments that include, but are not limited to, anticonvulsants, antidepressants, beta blockers, calcium channel blockers, botulinum toxins, NSAIDs, riboflavin, and magnesium. Patients may also benefit from adjunct nonpharmacological options in the comprehensive prevention of migraines, such as cognitive behavior therapy, relaxation therapies, biofeedback, lifestyle guidance, and education. Preventative therapies are an essential component of the overall approach to the pharmacological treatment of migraine. Comparative studies of newer therapies are needed to help patients receive the best treatment option for chronic migraine pain. (C) 2020 Published by Elsevier Ltd.
引用
收藏
页码：383 / 407
页数：25
相关论文
共 50 条
  • [31] Menstrual Migraine and Treatment Options: Review
    Maasumi, Kasra
    Tepper, Stewart J.
    Kriegler, Jennifer S.
    HEADACHE, 2017, 57 (02): : 194 - 208
  • [32] Entry demographics and pharmacological treatment of migraine patients referred to a tertiary care pain clinic
    Nijjar, S. S.
    Gordon, A. S.
    Clark, M. D.
    CEPHALALGIA, 2010, 30 (01) : 87 - 91
  • [33] Non-Pharmacological Approaches for Migraine
    Puledda, Francesca
    Shields, Kevin
    NEUROTHERAPEUTICS, 2018, 15 (02) : 336 - 345
  • [34] OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity
    Onan, Dilara
    Bentivegna, Enrico
    Martelletti, Paolo
    TOXINS, 2023, 15 (01)
  • [35] Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
    Turkel, Catherine C.
    Aurora, Sheena
    Diener, Hans-Christoph
    Dodick, David W.
    Lipton, Richard B.
    Silberstein, Stephen D.
    Brin, Mitchell F.
    MEDICINE, 2023, 102 : S59 - S66
  • [36] Pharmacological treatment of chronic pain - the need for CHANGE
    Varrassi, G.
    Mueller-Schwefe, G.
    Pergolizzi, J.
    Oronska, A.
    Morlion, B.
    Mavrocordatos, P.
    Margarit, C.
    Mangas, C.
    Jaksch, W.
    Huygen, F.
    Collett, B.
    Berti, M.
    Aldington, D.
    Ahlbeck, K.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (05) : 1231 - 1245
  • [37] Novel synthetic treatment options for migraine
    Negro, Andrea
    Martelletti, Paolo
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (07) : 907 - 922
  • [38] OnabotulinumtoxinA: Preventive Treatment for Chronic Migraine
    Chen, Shih-Pin
    Fuh, Jong-Ling
    Wang, Shuu-Jiun
    CURRENT PAIN AND HEADACHE REPORTS, 2011, 15 (01) : 4 - 7
  • [39] The beneficial effect of positive treatment expectations on pharmacological migraine prophylaxis
    Schmidt, Katharina
    Berding, Tobias
    Kleine-Borgmann, Julian
    Engler, Harald
    Holle-Lee, Dagny
    Gaul, Charly
    Bingel, Ulrike
    PAIN, 2022, 163 (02) : E319 - E327
  • [40] Emerging pharmacological treatment options for MAFLD
    Rojas, Angela
    Lara-Romero, Carmen
    Munoz-Hernandez, Rocio
    Gato, Sheila
    Ampuero, Javier
    Romero-Gomez, Manuel
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2022, 13
12345